Device And Drug Accelerated Approval Pathways Important To Cancer Patients, US FDA Oncology Chief Pazdur Says
Executive Summary
The Food and Drug Administration’s increased use of hastened approval pathways for innovative medical products, including new genomic device/drug combinations, has come in for criticism from some US Senators recently. But the patient group Friends of Cancer Research (FOCR) endorsed the approach at a 10 December meeting on Capitol Hill featuring FDA’s Oncology Center of Excellence director Richard Pazdur.